SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Clinical trials for SMALL LYMPHOCYTIC LYMPHOMA (SLL) explained in plain language.
Never miss a new study
Get alerted when new SMALL LYMPHOCYTIC LYMPHOMA (SLL) trials appear
Sign up with your email to follow new studies for SMALL LYMPHOCYTIC LYMPHOMA (SLL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat blood cancers: NX-5948 trial opens
Disease control Recruiting nowThis study tests an experimental drug called NX-5948 in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatments, including BTK and BCL-2 inhibitors. The main goal is to see if the drug can shrink o…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: PHASE2 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug takes aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase study tests a new drug called NX-5948 in adults with advanced B-cell blood cancers (like certain leukemias and lymphomas) that have not responded to other treatments. The drug works by breaking down a protein (BTK) that helps these cancer cells grow. The main goa…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New triple therapy aims to wipe out hidden CLL cells
Disease control Recruiting nowThis study tests a combination of three drugs (zanubrutinib, obinutuzumab, and sonrotoclax) in people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if the treatment can make the cancer undetectable in the bloo…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug takes aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a new oral drug called NX-2127 in adults with advanced B-cell cancers (like certain leukemias and lymphomas) that have not responded to standard treatments. The drug works by breaking down a protein that helps cancer cells grow. The main goals are to …
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for Tough-to-Treat blood cancers: targeted pill shows promise
Disease control Recruiting nowThis phase 2 trial tests the drug venetoclax (a pill) in 110 people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study includes two groups: those with a specific genetic change (17p deletion) and those who have failed oth…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug cocktail aims to wipe out hidden leukemia cells
Disease control Recruiting nowThis phase 2 trial is testing whether combining zanubrutinib and venetoclax can clear even trace amounts of cancer in people with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study enrolls 45 adults whose disease has returned afte…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New study probes how pirtobrutinib alters immune cells in blood cancer
Knowledge-focused Recruiting nowThis early-phase study is testing pirtobrutinib, a drug already approved for later-stage CLL/SLL, in 30 people who have not yet received any treatment. The main goal is to see how the drug changes immune cells in lymph nodes and blood, not to measure cure or symptom relief. Parti…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: EARLY_PHASE1 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
New study tracks daily life impact of CLL drugs over two years
Knowledge-focused Recruiting nowThis study follows 100 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) for two years to see how their quality of life, fatigue, and symptoms change after starting treatment. Researchers compare two drug types—BTK inhibitors and BCL-2 inhibitors—…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC